Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma
- PMID: 2147220
Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma
Abstract
The histologic and cytologic distinction of malignant mesothelioma from carcinomas metastatic to the pleura or peritoneum is often problematic. For this reason immunologic methods are being increasingly used as diagnostic adjuncts. This review summarizes 40 studies on the expression of carcinoembryonic antigen in mesotheliomas and in lung and other carcinomas involving the pleura or peritoneum. Carcinoembryonic antigen was identified immunohistochemically in 11% of mesotheliomas and in 84% of carcinomas examined and immunocytochemically (in serous effusions) in 4% and 58%, respectively. In serum and in pleural or ascitic fluid, significantly elevated levels of carcinoembryonic antigen are commonly associated with (lung) carcinomas but rarely with mesotheliomas. Thus, together with identification of the antigen in serum, pleural fluid, or ascitic fluid, immunohistochemical and immunocytochemical techniques for detecting carcinoembryonic antigen provide a valuable aid for distinguishing malignant mesothelioma from metastatic carcinomas.
Similar articles
-
Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.Arch Pathol Lab Med. 1996 Oct;120(10):959-66. Arch Pathol Lab Med. 1996. PMID: 12046609
-
[Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].Wien Klin Wochenschr. 1986 Sep 12;98(17):564-73. Wien Klin Wochenschr. 1986. PMID: 3020811 German.
-
Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients.J Pathol. 2001 Feb;193(2):175-80. doi: 10.1002/1096-9896(2000)9999:9999<::AID-PATH772>3.0.CO;2-T. J Pathol. 2001. PMID: 11180163
-
Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update.Adv Anat Pathol. 2006 Jan;13(1):16-25. doi: 10.1097/01.pap.0000201832.15591.1d. Adv Anat Pathol. 2006. PMID: 16462153 Review.
-
[Immunohistochemistry of mesotheliomas. Technique and current diagnostic contribution of immunohistochemical markers. General review].Arch Anat Cytol Pathol. 1993;41(5-6):212-22. Arch Anat Cytol Pathol. 1993. PMID: 8135582 Review. French.
Cited by
-
Diagnostic tests in pleural effusion--an update.Postgrad Med J. 1993 Jan;69(807):12-8. doi: 10.1136/pgmj.69.807.12. Postgrad Med J. 1993. PMID: 8446546 Free PMC article. Review. No abstract available.
-
Specificity of MOC-31 and HBME-1 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma: a study on environmental malignant mesothelioma cases from Turkish villages.Pathol Oncol Res. 2002;8(3):188-93. doi: 10.1007/BF03032393. Epub 2003 Jan 6. Pathol Oncol Res. 2002. PMID: 12515999
-
Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions.Br J Cancer. 1998;77(3):472-6. doi: 10.1038/bjc.1998.75. Br J Cancer. 1998. PMID: 9472646 Free PMC article.
-
Value of serum and effusion fluid CEA levels for distinguishing between diffuse malignant mesothelioma and carcinomatous pleural metastases.Lung. 1994;172(3):183-4. doi: 10.1007/BF00175946. Lung. 1994. PMID: 8201832 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical